Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study

IF 4 2区医学 Q1 DENTISTRY, ORAL SURGERY & MEDICINE

Oral oncology Pub Date : 2024-09-18 DOI:10.1016/j.oraloncology.2024.107028

Yu Min , Xiaoxia Liu , Zhigong Wei , Ge Song , Yuantai Li , Kun Gao , Zheran Liu , Yiyan Pei , Huilin Li , Junyou Ge , Yan Qing , Youneng Wei , Xingchen Peng

{"title":"Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study","authors":"Yu Min , Xiaoxia Liu , Zhigong Wei , Ge Song , Yuantai Li , Kun Gao , Zheran Liu , Yiyan Pei , Huilin Li , Junyou Ge , Yan Qing , Youneng Wei , Xingchen Peng","doi":"10.1016/j.oraloncology.2024.107028","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Immune-related biomarkers are linked to the outcomes of cancer immunotherapy. This study evaluates the baseline and longitudinal association between the lung immune prognostic index (LIPI) and immune checkpoint inhibitor outcomes in previously treated recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) patients.</p></div><div><h3>Methods</h3><p>Data from 153 R/M NPC patients (median age = 49.00 years old) enrolled in a multicenter, single-arm, phase 2 study (NCT03848286) were analyzed. Pretreatment LIPI was classified into good and intermediate/poor (inter/poor) groups. Longitudinal LIPI variations were categorized into “Stable good”, “Trend to increase”, “Trend to decrease”, and “Stable inter/poor”. Primary and secondary outcomes were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR).</p></div><div><h3>Results</h3><p>Pretreatment LIPI was significantly associated with OS (inter/poor vs. good: HR = 2.54, 95 % CI: 1.60–4.04, P < 0.001), PFS [inter/poor vs. good: hazard ratio (HR) = 2.18, 95 % CI: 1.47–3.23, P < 0.001], and DCR [inter/poor vs. good: odd ratio (OR) = 0.26, 95 % CI: 0.12–0.58, P < 0.001)]. Patients with persistently inter/poor LIPI status showed worse OS (HR = 3.25, 95 % CI: 1.84–5.74, P < 0.001), PFS (HR = 2.96, 95 % CI: 1.85–4.74, P < 0.001), and ORR (OR = 0.21, 95 % CI: 0.08–0.56, P < 0.001) compared to the persistently good subgroup.</p></div><div><h3>Conclusion</h3><p>Pretreatment LIPI and its longitudinal variations may serve as potential biomarkers for predicting immune checkpoint inhibitor outcomes in R/M NPC patients.</p></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"159 ","pages":"Article 107028"},"PeriodicalIF":4.0000,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1368837524003464","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DENTISTRY, ORAL SURGERY & MEDICINE","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Immune-related biomarkers are linked to the outcomes of cancer immunotherapy. This study evaluates the baseline and longitudinal association between the lung immune prognostic index (LIPI) and immune checkpoint inhibitor outcomes in previously treated recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) patients.

Methods

Data from 153 R/M NPC patients (median age = 49.00 years old) enrolled in a multicenter, single-arm, phase 2 study (NCT03848286) were analyzed. Pretreatment LIPI was classified into good and intermediate/poor (inter/poor) groups. Longitudinal LIPI variations were categorized into “Stable good”, “Trend to increase”, “Trend to decrease”, and “Stable inter/poor”. Primary and secondary outcomes were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR).

Results

Pretreatment LIPI was significantly associated with OS (inter/poor vs. good: HR = 2.54, 95 % CI: 1.60–4.04, P < 0.001), PFS [inter/poor vs. good: hazard ratio (HR) = 2.18, 95 % CI: 1.47–3.23, P < 0.001], and DCR [inter/poor vs. good: odd ratio (OR) = 0.26, 95 % CI: 0.12–0.58, P < 0.001)]. Patients with persistently inter/poor LIPI status showed worse OS (HR = 3.25, 95 % CI: 1.84–5.74, P < 0.001), PFS (HR = 2.96, 95 % CI: 1.85–4.74, P < 0.001), and ORR (OR = 0.21, 95 % CI: 0.08–0.56, P < 0.001) compared to the persistently good subgroup.

Conclusion

Pretreatment LIPI and its longitudinal variations may serve as potential biomarkers for predicting immune checkpoint inhibitor outcomes in R/M NPC patients.

查看原文本刊更多论文

肺部免疫预后指数与接受免疫疗法的复发性或转移性鼻咽癌（R/M）的临床预后有关：多中心、单臂、2 期研究的结果

背景免疫相关生物标志物与癌症免疫疗法的结果有关。本研究评估了既往接受过治疗的复发性或转移性（R/M）鼻咽癌（NPC）患者的肺免疫预后指数（LIPI）与免疫检查点抑制剂疗效之间的基线和纵向关联。方法分析了一项多中心、单臂、2期研究（NCT03848286）中入组的153名R/M NPC患者（中位年龄=49.00岁）的数据。治疗前 LIPI 分为良好组和中间/差（中间/差）组。LIPI的纵向变化分为 "稳定良好组"、"趋势增加组"、"趋势减少组 "和 "稳定中间/差组"。主要和次要结果为总生存期（OS）、无进展生存期（PFS）、客观反应率（ORR）和疾病控制率（DCR）。治疗前 LIPI 与 OS（贫间期与良期：HR = 2.54，95 % CI：1.60-4.04，P < 0.001）、PFS [贫间期与良期：危险比 (HR) = 2.18，95 % CI：1.47-3.23，P < 0.001]和 DCR [贫间期与良期：奇数比 (OR) = 0.26，95 % CI：0.12-0.58，P < 0.001]显著相关。］LIPI 状态持续为间/差的患者的 OS（HR = 3.25，95 % CI：1.84-5.74，P < 0.001）、PFS（HR = 2.96，95 % CI：1.85-4.74，P < 0.001）和 ORR（OR = 0.21，95 % CI：0.08-0.56，P < 0.001）。结论治疗前 LIPI 及其纵向变化可作为预测 R/M NPC 患者免疫检查点抑制剂预后的潜在生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oral oncology 医学-牙科与口腔外科

CiteScore

8.70

自引率

10.40%

发文量

505

审稿时长

20 days

期刊介绍： Oral Oncology is an international interdisciplinary journal which publishes high quality original research, clinical trials and review articles, editorials, and commentaries relating to the etiopathogenesis, epidemiology, prevention, clinical features, diagnosis, treatment and management of patients with neoplasms in the head and neck. Oral Oncology is of interest to head and neck surgeons, radiation and medical oncologists, maxillo-facial surgeons, oto-rhino-laryngologists, plastic surgeons, pathologists, scientists, oral medical specialists, special care dentists, dental care professionals, general dental practitioners, public health physicians, palliative care physicians, nurses, radiologists, radiographers, dieticians, occupational therapists, speech and language therapists, nutritionists, clinical and health psychologists and counselors, professionals in end of life care, as well as others interested in these fields.